Oppenheimer analyst Hartaj Singh initiated coverage of Icosavax with an Outperform rating and $27 price target. Icosavax is a vaccine company with a "scalable" antigenic delivery platform, focusing on underserved populations with high unmeet needs, Singh tells investors in a research note. The company exits 2022 with "robust" Phase 1 data in respiratory syncytial virus, and with six-month durability, says the analyst. In 2023, Singh expects proof-of-concept in bivalent RSV and human metapneumovirus and 12-month RSV data. "We are bullish," the analyst writes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ICVX:
- Icosavax reports durability data for VLP vaccine IVX-121 against RSV
- Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint
- Icosavax reports Q3 EPS (55c), consensus (57c)
- Icosavax Reports Third Quarter Financial Results and Provides Corporate Update
- Icosavax to Participate in in Upcoming Investor Conferences